Exscientia Plc Revenue Growth Rates (EXAI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Exscientia Plc  (NASDAQ: EXAI)
 

EXAI's Revenue Growth by Quarter and Year

Exscientia Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EXAI Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 6.41
2nd Quarter June 5.58
1st Quarter March 3.02
FY 15.01





EXAI Revenue third quarter 2024 Y/Y Growth Comment
Exscientia Plc achieved in the third quarter 2024, above Company average Revenue rise of 70.51% year on year, to $ 6.41 millions.

Looking into third quarter 2024 results within Biotechnology & Pharmaceuticals industry 59 other companies have achieved higher Revenue growth. While Exscientia Plc' s Revenue jump of 70.51% ranks overall at the positon no. 4148 in the third quarter 2024.


EXAI Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 51.82 % -69.52 % -
3rd Quarter September 70.51 % -58.08 % 2087.8 % -
2nd Quarter June -20.29 % -25.13 % 28.26 % -
1st Quarter March -62.3 % - - -
FY   - 16.67 % -19.62 % -

Financial Statements
Exscientia Plc's third quarter 2024 Revenue $ 6.41 millions EXAI's Income Statement
Exscientia Plc's third quarter 2023 Revenue $ 3.76 millions Quarterly EXAI's Income Statement


EXAI Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 199.2 % -17.39 % 5829.27 %
3rd Quarter September 14.9 % -46.29 % -4.06 % -94.38 %
2nd Quarter June 84.77 % -12.61 % - -
1st Quarter March -73.16 % 8.1 % - -
FY (Year on Year)   - 16.67 % -19.62 % -


Back to EXAI Growth rate Comparisons >> Back to EXAI Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #60
Healthcare Sector #579
Overall #4148

Revenue Y/Y Growth Statistics
High Average Low
-25.83 % -25.83 % -25.83 %
(Dec 31 2023)  
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #60
Healthcare Sector #579
Overall #4148
Revenue Y/Y Growth Statistics
High Average Low
-25.83 % -25.83 % -25.83 %
(Dec 31 2023)  

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Exscientia Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
5856.33 % 520.95 % -100 %
0  


EXAI's III. Quarter Q/Q Revenue Comment
Exscientia Plc achieved in the III. Quarter 2024 below company average Revenue rise of 14.9% quarter on quarter, to $ 6.41 millions.

Although the III. Quarter 2024 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -46.29% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Exscientia Plc's Revenue growth quarter on quarter, overall rank is 957.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #234
Overall #957
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #234
Overall #957
Revenue Q/Q Growth Statistics
High Average Low
5856.33 % 520.95 % -100 %
0  


EXAI's III. Quarter Q/Q Revenue Comment
Exscientia Plc achieved in the III. Quarter 2024 below company average Revenue rise of 14.9% quarter on quarter, to $ 6.41 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -46.29% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Exscientia Plc's Revenue growth quarter on quarter, overall rank is 957.


Exscientia Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 24.98 $ 33.68 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) -25.83 % - - - -
Year on Year Revenue Growth Overall Ranking # 4148 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -25.83 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 4148 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Exscientia Plc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2022. If the fiscal year would end in Dec 31 2023, Exscientia Plc's annual Revenue drop would be -25.83% year on year to $25 millions.

In the Healthcare sector 578 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4148.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 60
Healthcare Sector # 579
Overall # 4148

Revenue TTM Y/Y Growth Statistics
High Average Low
-25.83 %
 -25.83 %
-25.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 579
S&P 500 # 4148
Cumulative Revenue growth Comment
Exscientia Plc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2022. If the fiscal year would end in Dec 31 2023, Exscientia Plc's annual Revenue drop would be -25.83% year on year to $25 millions.

In the Healthcare sector 578 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4148.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 60
Healthcare Sector # 579
Overall # 4148

Revenue TTM Y/Y Growth Statistics
High Average Low
-25.83 %
-25.83 %
-25.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 579
S&P 500 # 4148




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EXAI's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Verve Therapeutics Inc 120.24%$ 120.244 millions
Meiragtx Holdings Plc113.80%$ 113.796 millions
Celldex Therapeutics inc 110.35%$ 110.349 millions
Veru Inc 105.35%$ 105.350 millions
Safe Pro Group Inc 102.30%$ 102.297 millions
Ss Innovations International Inc100.57%$ 100.572 millions
Abeona Therapeutics Inc 100.51%$ 100.506 millions
Myomo Inc 99.28%$ 99.284 millions
Rigel Pharmaceuticals Inc96.58%$ 96.584 millions
Biofrontera Inc 94.96%$ 94.964 millions
Yunhong Green Cti Ltd 94.12%$ 94.118 millions
Mirum Pharmaceuticals Inc 89.37%$ 89.370 millions
Sanuwave Health Inc 88.98%$ 88.976 millions
Nexgel Inc 86.90%$ 86.896 millions
Anavex Life Sciences Corp 86.30%$ 86.300 millions
Axsome Therapeutics Inc 81.27%$ 81.268 millions
Adma Biologics Inc 79.53%$ 79.526 millions
Apellis Pharmaceuticals Inc 78.29%$ 78.290 millions
Hims and Hers Health Inc 77.14%$ 77.142 millions
Standard Biotools Inc 75.96%$ 75.960 millions
Ardelyx inc 74.21%$ 74.214 millions
Arcellx Inc 74.03%$ 74.032 millions
Protalix Biotherapeutics inc 73.60%$ 73.601 millions
Evoke Pharma Inc 69.83%$ 69.829 millions
Travere Therapeutics Inc 69.56%$ 69.559 millions
Alector Inc 68.43%$ 68.427 millions
Kiniksa Pharmaceuticals International Plc67.37%$ 67.369 millions
Procept Biorobotics Corporation66.06%$ 66.058 millions
Natera Inc 63.90%$ 63.902 millions
Transmedics Group Inc 63.72%$ 63.723 millions


About Exscientia Plc Revenue Growth Rates (EXAI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Exscientia Plc (CIK 1865408).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001865408-24-000018
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Exscientia Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.